keyword
MENU ▼
Read by QxMD icon Read
search

cystic fibrosis antibiotics

keyword
https://www.readbyqxmd.com/read/29218501/evaluating-safety-reporting-in-paediatric-antibiotic-trials-2000-2016-a-systematic-review-and-meta-analysis
#1
REVIEW
Paola Pansa, Yingfen Hsia, Julia Bielicki, Irja Lutsar, A Sarah Walker, Mike Sharland, Laura Folgori
BACKGROUND: There are very few options to treat multidrug-resistant bacterial infections in children. A major barrier is the duration and complexity of regulatory trials of new antibiotics. Extrapolation of safety data from adult trials could facilitate drug development for children. OBJECTIVE: We performed a systematic review on the safety of antibiotic clinical trials (CTs) in children (0-18 years) to evaluate the overall quality of safety trials conducted in children and to determine if age-specific adverse events (AEs) could be identified for specific antibiotic classes...
December 7, 2017: Drugs
https://www.readbyqxmd.com/read/29204272/novel-antibiotic-combinations-proposed-for-treatment-of-burkholderia-cepacia-complex-infections
#2
Omar M El-Halfawy, Marwa M Naguib, Miguel A Valvano
Effective strategies to manage Burkholderia cepacia complex (Bcc) infections in cystic fibrosis (CF) patients are lacking. We tested combinations of clinically available antibiotics and show that moxifloxacin-ceftazidime could inhibit 16 Bcc clinical isolates at physiologically achievable concentrations. Adding low dose of colistin improved the efficacy of the combo, especially at conditions mimicking CF respiratory secretions.
2017: Antimicrobial Resistance and Infection Control
https://www.readbyqxmd.com/read/29187171/antibiotic-duration-and-changes-in-fev1-are-not-associated-with-time-until-next-exacerbation-in-adult-cystic-fibrosis-a-single-center-study
#3
Julia C Espel, Hannah L Palac, Joanne F Cullina, Alexandria P Clarke, Susanna A McColley, Michelle H Prickett, Manu Jain
BACKGROUND: Pulmonary exacerbations (PEx) are a major driver of morbidity and mortality in cystic fibrosis and reducing their frequency by extending the time between them is an important therapeutic goal. Although treatment decisions for exacerbations are often made based on dynamic changes in lung function, it is not clear if these changes truly impact future exacerbation risk. We analyzed adults with chronic Pseudomonas aeruginosa infection to determine whether changes in FEV1 or duration of intravenous antibiotic therapy were associated with time to the next pulmonary exacerbation...
November 29, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29185854/molecular-epidemiology-of-methicillin-resistant-staphylococcus-aureus-in-cystic-fibrosis-patients-from-argentina
#4
Paula Pena Amaya, Maria S Haim, Silvina Fernández, Sabrina Di Gregorio, Alejandro Teper, Miryam Vázquez, Silvina Lubovich, Laura Galanternik, Marta Mollerach
Methicillin-resistant Staphylococcus aureus (MRSA) colonization in cystic fibrosis (CF) patients is an increasing problem in many countries. In our Respiratory Center at the Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina, the prevalence has climbed from 23% in 1995 up to 32% in 2011. Our objective was to analyze the diversity of MRSA isolates recovered from respiratory samples of CF patients attending our center, characterizing their phenotypes and clonal distribution. Therefore, a prospective study was conducted on all CF patients attending the pediatric Respiratory Center between June 2012 and May 2013 to collect MRSA isolates...
November 29, 2017: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/29183160/daily-spirometry-in-an-acute-exacerbation-of-adult-cystic-fibrosis-patients
#5
Michael J Stephen, Alex Long, Chad Bonsall, Jeffrey B Hoag, Smita Shah, Dorothy Bisberg, Douglas Holsclaw, Laurie Varlotta, Stan Fiel, Doantrang Du, Robert Zanni, Denis Hadjiliadis
To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10% increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10% increase in FEV1...
January 1, 2017: Chronic Respiratory Disease
https://www.readbyqxmd.com/read/29176757/pseudomonas-aeruginosa-exoproducts-determine-antibiotic-efficacy-against-staphylococcus-aureus
#6
Lauren Radlinski, Sarah E Rowe, Laurel B Kartchner, Robert Maile, Bruce A Cairns, Nicholas P Vitko, Cindy J Gode, Anne M Lachiewicz, Matthew C Wolfgang, Brian P Conlon
Chronic coinfections of Staphylococcus aureus and Pseudomonas aeruginosa frequently fail to respond to antibiotic treatment, leading to significant patient morbidity and mortality. Currently, the impact of interspecies interaction on S. aureus antibiotic susceptibility remains poorly understood. In this study, we utilize a panel of P. aeruginosa burn wound and cystic fibrosis (CF) lung isolates to demonstrate that P. aeruginosa alters S. aureus susceptibility to bactericidal antibiotics in a variable, strain-dependent manner and further identify 3 independent interactions responsible for antagonizing or potentiating antibiotic activity against S...
November 27, 2017: PLoS Biology
https://www.readbyqxmd.com/read/29174734/rpob-gene-sequencing-highlights-the-prevalence-of-an-e-miricola-cluster-over-other-elizabethkingia-species-among-uk-cystic-fibrosis-patients
#7
Dervla T D Kenna, Alice Fuller, Kate Martin, Claire Perry, Rachel Pike, Phillipa J Burns, Omendra Narayan, Stuart Wilkinson, Robert Hill, Neil Woodford, Julie M J Logan, Jane F Turton
Difficulties in distinguishing species of the Elizabethkingia genus by MALDI-TOF prompted use of rpoB sequencing to investigate species distribution among 44 isolates from cystic fibrosis (CF) patients. Forty-three isolates from 38 patients formed a cluster comprising E. miricola and proposed novel species E. bruuniana sp. nov., the exception clustering with proposed species E. ursingii sp. nov., also part of this wider cluster. All 44 isolates were PCR-positive for urease gene ureG, whereas only one of 23 E...
October 26, 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29174082/multiple-reaction-monitoring-mass-spectrometry-to-identify-novel-plasma-protein-biomarkers-of-treatment-response-in-cystic-fibrosis-pulmonary-exacerbations
#8
James M Roberts, Darlene L Y Dai, Zsuzsanna Hollander, Raymond T Ng, Scott J Tebbutt, Pearce G Wilcox, Don D Sin, Bradley S Quon
BACKGROUND: Systemic inflammation decreases with IV antibiotics during the treatment of CF pulmonary exacerbations (PEx). We used multiple reaction monitoring mass spectrometry and immunoassays to monitor blood proteins during PEx treatment to determine if early changes could be used to predict PEx outcomes following treatment. METHODS: Blood samples from 25 PEx (22 unique adults) were collected within 24h of admission, day 5, day 10, and at IV antibiotic completion...
November 21, 2017: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://www.readbyqxmd.com/read/29170074/study-design-considerations-for-the-standardized-treatment-of-pulmonary-exacerbations-2-stop2-a-trial-to-compare-intravenous-antibiotic-treatment-durations-in-cf
#9
Sonya L Heltshe, Natalie E West, Donald R VanDevanter, D B Sanders, Valeria V Beckett, Patrick A Flume, Christopher H Goss
BACKGROUND: Pulmonary exacerbations (PEx) in cystic fibrosis (CF) are common and contribute to morbidity and mortality. Duration of IV antibiotic therapy to treat PEx varies widely in the US, and there are few data to guide treatment decisions. METHODS: We combined a survey of CF stakeholders with retrospective analyses of a recent observational study of CF PEx to design a multicenter, randomized, prospective study comparing the efficacy and safety of different durations of IV antibiotics for PEx to meet the needs of people with CF and their caregivers...
November 20, 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29163413/lipoprotein-glycosylation-by-protein-o-mannosyltransferase-mab_1122c-contributes-to-low-cell-envelope-permeability-and-antibiotic-resistance-of-mycobacterium-abscessus
#10
Katja Becker, Klara Haldimann, Petra Selchow, Lukas M Reinau, Michael Dal Molin, Peter Sander
Lipoproteins are important components of the mycobacterial cell envelope due to their function in cell wall homeostasis and bacterial virulence. They are post-translationally modified with lipid- and glycosyl-residues in various species and interference with acylation or glycosylation leads to reduced growth and attenuated virulence in Mycobacterium tuberculosis. Lipoproteins are also expressed in the emerging and highly drug resistant pathogen Mycobacterium abscessus which frequently affects the lungs of patients with chronic pulmonary disease or cystic fibrosis...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29143505/-inhaled-antibiotics-for-the-management-of-non-cystic-fibrosis-bronchiectasis
#11
Gregory Berra, Émilie Chappuis-Gisin, Paola M Soccal, Jérôme Plojoux
Bronchiectasis is irreversible bronchial dilatation associated with chronic respiratory symptoms. Management is aimed at reducing symptoms and slowing the progression of the disease by interrupting the vicious circle: bronchial infection, inflammation, altered mucociliary clearance, lung destruction. Unlike the literature on inhaled antibiotics in cystic fibrosis, literature data are limited and of low quality for bronchiectasis of other causes. However, new recommendations from the European Respiratory Society propose the conditional use of inhaled antibiotics to prevent repeated infectious exacerbations and to eradicate Pseudomonas aeruginosa colonization...
November 15, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29138462/the-antibacterial-and-anti-inflammatory-activity-of-chicken-cathelicidin-2-combined-with-exogenous-surfactant-for-the-treatment-of-cystic-fibrosis-associated-pathogens
#12
Brandon J H Banaschewski, Brandon Baer, Christina Arsenault, Teah Jazey, Edwin J A Veldhuizen, Johan Delport, Tracey Gooyers, James F Lewis, Henk P Haagsman, Ruud A W Veldhuizen, Cory Yamashita
Cystic fibrosis (CF) is characterized by recurrent airway infections with antibiotic-resistant bacteria and chronic inflammation. Chicken cathelicin-2 (CATH-2) has been shown to exhibit antimicrobial activity against antibiotic-resistant bacteria and to reduce inflammation. In addition, exogenous pulmonary surfactant has been suggested to enhance pulmonary drug delivery. It was hypothesized that CATH-2 when combined with an exogenous surfactant delivery vehicle, bovine lipid extract surfactant (BLES), would exhibit antimicrobial activity against CF-derived bacteria and downregulate inflammation...
November 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29127619/changes-in-the-lung-bacteriome-in-relation-to-antipseudomonal-therapy-in-children-with-cystic-fibrosis
#13
Lenka Kramná, Pavel Dřevínek, Jake Lin, Michal Kulich, Ondrej Cinek
The lung in cystic fibrosis (CF) is home to numerous pathogens that shorten the lives of patients. The aim of the present study was to assess changes in the lung bacteriome following antibiotic therapy targeting Pseudomonas aeruginosa in children with CF. The study included nine children (9-18 years) with CF who were treated for their chronic or intermittent positivity for Pseudomonas aeruginosa. The bacteriomes were determined in 16 pairs of sputa collected at the beginning and at the end of a course of intravenous antibiotic therapy via deep sequencing of the variable region 4 of the 16S rRNA gene, and the total bacterial load and selected specific pathogens were assessed using quantitative real-time PCR...
November 10, 2017: Folia Microbiologica
https://www.readbyqxmd.com/read/29126871/lumacaftor-ivacaftor-in-patients-with-cystic-fibrosis-and-advanced-lung-disease-homozygous-for-f508del-cftr
#14
Jennifer L Taylor-Cousar, Manu Jain, Tara Lynn Barto, Tarik Haddad, Jeffrey Atkinson, Simon Tian, Rui Tang, Gautham Marigowda, David Waltz, Joseph Pilewski
OBJECTIVE: Evaluation of the safety, tolerability, and efficacy of lumacaftor/ivacaftor in patients with cystic fibrosis (CF) with severe lung disease. METHODS: Patients with CF 12 years of age and older, homozygous for F508del-CFTR, with percent predicted forced expiratory volume in 1 second (ppFEV1) <40 received lumacaftor 400 mg/ivacaftor 250mg every 12h (full dose) for 24weeks in an open-label, prospective study (NCT02390219). Dose modification to half dose for 1-2weeks (including at initiation) was permitted...
November 7, 2017: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://www.readbyqxmd.com/read/29121069/developing-selective-media-for-quantification-of-multispecies-biofilms-following-antibiotic-treatment
#15
Eva Vandeplassche, Tom Coenye, Aurélie Crabbé
The lungs of cystic fibrosis (CF) patients are chronically colonized by a polymicrobial biofilm community, leading to difficult-to-treat infections. To combat these infections, CF patients are commonly treated with a variety of antibiotics. Understanding the dynamics of polymicrobial community composition in response to antibiotic therapy is essential in the search for novel therapies. Culture-dependent quantification of individual bacteria from defined multispecies biofilms is frequently carried out by plating on selective media...
2017: PloS One
https://www.readbyqxmd.com/read/29112974/impact-of-extensive-antibiotic-treatment-on-faecal-carriage-of-antibiotic-resistant-enterobacteria-in-children-in-a-low-resistance-prevalence-setting
#16
Per Kristian Knudsen, Petter Brandtzaeg, E Arne Høiby, Jon Bohlin, Ørjan Samuelsen, Martin Steinbakk, Tore G Abrahamsen, Fredrik Müller, Karianne Wiger Gammelsrud
We prospectively studied the consequences of extensive antibiotic treatment on faecal carriage of antibiotic-resistant enterobacteria in a cohort of children with cystic fibrosis (CF) and a cohort of children with cancer compared to healthy children with no or low antibiotic exposure. The study was conducted in Norway in a low resistance prevalence setting. Sixty longitudinally collected faecal samples from children with CF (n = 32), 88 samples from children with cancer (n = 45) and 127 samples from healthy children (n = 70) were examined...
2017: PloS One
https://www.readbyqxmd.com/read/29111673/nano-into-micro-formulations-of-tobramycin-for-the-treatment-of-pseudomonas-aeruginosa-infections-in-cystic-fibrosis
#17
Barbara Porsio, Maria Grazia Cusimano, Domenico Schillaci, Emanuela Fabiola Craparo, Gaetano Giammona, Gennara Cavallaro
Here, nano into micro formulations (NiMs) of tobramycin for the treatment of Pseudomonas aeruginosa airway infections in cystic fibrosis (CF) are described. NiMs were produced by spray drying a solution containing polymers or sugars and a nanometric Polyanion-Tobramcyin Complex (PTC), able to achieve a prolonged antibiotic release. NiMs properties were compared to TOBI®Podhaler®(Novartis), the only one commercially available dry powder inhalatory formulation based on porous microparticles. Produced NiMs showed adequate characteristics for pulmonary administration, as spherical shape, micrometric size and high cytocompatibility towards human bronchial epithelial cells...
November 7, 2017: Biomacromolecules
https://www.readbyqxmd.com/read/29110790/long-term-management-of-patients-with-end-stage-lung-diseases
#18
REVIEW
Domenica Federica Briganti, Frank D'Ovidio
Long-term management of end-stage lung disease differs from interstitial lung disease to chronic obstructive pulmonary disease to cystic fibrosis to pulmonary vascular disease. The management includes pharmacological therapy that is disease specific such as antibiotic therapy for cystic fibrosis, antifibrotic drugs in idiopathic pulmonary fibrosis; long-acting beta-agonists, long-acting muscarinic antagonist, and inhaled corticosteroids in chronic obstructive pulmonary disease; and vasodilators in pulmonary arterial hypertension...
June 2017: Best Practice & Research. Clinical Anaesthesiology
https://www.readbyqxmd.com/read/29107983/synthetic-host-defense-peptide-idr-1002-reduces-inflammation-in-pseudomonas-aeruginosa-lung-infection
#19
Kelli C Wuerth, Reza Falsafi, Robert E W Hancock
Pseudomonas aeruginosa is a frequent cause of lung infections, particularly in chronic infections in cystic fibrosis patients. However, treatment is challenging due to P. aeruginosa evasion of the host immune system and the rise of antibiotic resistant strains. Host defense peptides (HDPs) and synthetic derivatives called innate defense regulators (IDRs) have shown promise in several infection models as an alternative to antibiotic treatment. Here we tested peptide IDR-1002 against P. aeruginosa in vitro and in vivo...
2017: PloS One
https://www.readbyqxmd.com/read/29098998/the-emergence-of-multidrug-resistant-pseudomonas-aeruginosa-in-cystic-fibrosis-patients-on-inhaled-antibiotics
#20
Atqah AbdulWahab, Khalid Zahraldin, Mazen A Sid Ahmed, Sulieman Abu Jarir, Mohammed Muneer, Shehab F Mohamed, Jemal M Hamid, Abubaker A I Hassan, Emad Bashir Ibrahim
INTRODUCTION: Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is an important and growing issue in the care of patients with cystic fibrosis (CF), and a major cause of morbidity and mortality. OBJECTIVE: The objective of the study was to describe the frequency of MDR-PA recovered from the lower respiratory samples of pediatric and adult CF patients, and its antibiotic resistance pattern to commonly used antimicrobial agents including β-lactams, aminoglycosides, and fluoroquinolones...
November 2017: Lung India: Official Organ of Indian Chest Society
keyword
keyword
49489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"